Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Similar articles for PubMed (Select 23407048)

1.

The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity.

Ho HT, Wang TH, Hsiong CH, Perng WC, Wang NC, Huang TY, Jong YJ, Lu PL, Hu OY.

Pharmacogenet Genomics. 2013 Apr;23(4):200-7. doi: 10.1097/FPC.0b013e32835e95e1.

PMID:
23407048
2.

Pharmacogenetics of isoniazid-induced hepatotoxicity.

Perwitasari DA, Atthobari J, Wilffert B.

Drug Metab Rev. 2015 May;47(2):222-8. doi: 10.3109/03602532.2014.984070. Epub 2014 Nov 19.

PMID:
26095714
3.

Determination of NAT2 acetylation status in the Greenlandic population.

Geller F, Soborg B, Koch A, Michelsen SW, Bjorn-Mortensen K, Carstensen L, Birch E, Nordholm AC, Johansen MM, Børresen ML, Feenstra B, Melbye M.

Arch Toxicol. 2015 Mar 21. [Epub ahead of print]

PMID:
25794903
4.

Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.

Guaoua S, Ratbi I, Laarabi FZ, Elalaoui SC, Jaouad IC, Barkat A, Sefiani A.

BMC Genet. 2014 Dec 29;15:156. doi: 10.1186/s12863-014-0156-x.

5.

[Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].

Negri L, Le Grusse J, Séraissol P, Lavit M, Houin G, Gandia P.

Therapie. 2014 Nov-Dec;69(6):509-16. doi: 10.2515/therapie/2014202. Epub 2014 Oct 16. French.

PMID:
25314930
6.

Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population.

Tekola-Ayele F, Adeyemo A, Aseffa A, Hailu E, Finan C, Davey G, Rotimi CN, Newport MJ.

Pharmacogenomics J. 2015 Feb;15(1):101-8. doi: 10.1038/tpj.2014.39. Epub 2014 Jul 29.

PMID:
25069476
7.

N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.

Mishra S, Daschakraborty S, Shukla P, Kapoor P, Aggarwal R.

Natl Med J India. 2013 Sep-Oct;26(5):260-5.

PMID:
25017831
8.

GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence.

Eny KM, Lutgers HL, Maynard J, Klein BE, Lee KE, Atzmon G, Monnier VM, van Vliet-Ostaptchouk JV, Graaff R, van der Harst P, Snieder H, van der Klauw MM, Sell DR, Hosseini SM, Cleary PA, Braffett BH, Orchard TJ, Lyons TJ, Howard K, Klein R, Crandall JP, Barzilai N, Milman S, Ben-Avraham D; LifeLines Cohort Study Group; DCCT/EDIC Research Group, Wolffenbuttel BH, Paterson AD.

Diabetologia. 2014 Aug;57(8):1623-34. doi: 10.1007/s00125-014-3286-9. Epub 2014 Jun 17.

9.

N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.

Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, Aithal GP, Daly AK.

Eur J Clin Pharmacol. 2014 Sep;70(9):1079-86. doi: 10.1007/s00228-014-1703-0. Epub 2014 Jun 3.

PMID:
24888881
10.

Future of pharmacogenetics-based therapy for tuberculosis.

Matsumoto T, Ohno M, Azuma J.

Pharmacogenomics. 2014 Apr;15(5):601-7. doi: 10.2217/pgs.14.38. Review.

PMID:
24798717
11.

The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients.

Zaverucha-do-Valle C, Monteiro SP, El-Jaick KB, Rosadas LA, Costa MJ, Quintana MS, de Castro L.

Tuberculosis (Edinb). 2014 May;94(3):299-305. doi: 10.1016/j.tube.2014.03.006. Epub 2014 Apr 1.

PMID:
24793319
12.

Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.

Boelsterli UA, Lee KK.

J Gastroenterol Hepatol. 2014 Apr;29(4):678-87. Review.

PMID:
24783247
13.

Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.

Singla N, Gupta D, Birbian N, Singh J.

Tuberculosis (Edinb). 2014 May;94(3):293-8. doi: 10.1016/j.tube.2014.02.003. Epub 2014 Feb 15.

PMID:
24637014
14.

The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.

Sheng YJ, Wu G, He HY, Chen W, Zou YS, Li Q, Zhong L, Huang YM, Deng CL.

Infect Genet Evol. 2014 Jun;24:34-40. doi: 10.1016/j.meegid.2014.01.034. Epub 2014 Mar 6.

PMID:
24607341
15.

Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury.

Huang YS.

J Chin Med Assoc. 2014 Apr;77(4):169-73. doi: 10.1016/j.jcma.2014.01.010. Epub 2014 Mar 1.

PMID:
24593909
16.

Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis.

Verhagen LM, Coenen MJ, López D, García JF, de Waard JH, Schijvenaars MM, Hermans PW, Aarnoutse RE.

Pharmacogenomics. 2014 Feb;15(3):285-96. doi: 10.2217/pgs.13.230.

PMID:
24533708
17.

Improvements in algorithms for phenotype inference: the NAT2 example.

Selinski S, Blaszkewicz M, Ickstadt K, Hengstler JG, Golka K.

Curr Drug Metab. 2014 Feb;15(2):233-49.

PMID:
24524665
18.
19.

Association of genetic variants with anti-tuberculosis drug induced hepatotoxicity: a high resolution melting analysis.

Singh M, Gupta VH, Amarapurkar DN, Joshi JM, Baijal R, Ramegowda PH, Amarapurkar AD, Wangikar PP.

Infect Genet Evol. 2014 Apr;23:42-8. doi: 10.1016/j.meegid.2014.01.027. Epub 2014 Jan 31.

PMID:
24491431
20.

The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.

Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, Wang Q, Ma J, Cao M, Wang Q, Yao X, Yang L, Wubuli A, Merle C, Milligan P, Mao Y, Gu J, Xin X.

PLoS One. 2014 Jan 23;9(1):e85905. doi: 10.1371/journal.pone.0085905. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk